QuantumLeap Healthcare Collaborative

Birmingham, Alabama

OncologyPhase II

What changed

Phase II trial registered: DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

8w agoTrial registeredMay 22, 2026Source filing (opens the source filing in a new tab)

Momentum

78no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R13 · $13k · non-dilutive
Feb 9, 2026
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ESSERMAN, LAURA J · NCI · award ends Jan 31, 2027 · RISE UP for Breast Cancer 2026
NIH RePORTER · NIH RePORTER 11321058 (opens the source filing in a new tab)
Trial
PHASE2 registered
Feb 17, 2024
Ductal Carcinoma in Situ · RECRUITING · sponsor: QuantumLeap Healthcare Collaborative · DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
ClinicalTrials.gov · NCT06075953 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jul 31, 2020
COVID-19 · ACTIVE_NOT_RECRUITING · sponsor: QuantumLeap Healthcare Collaborative · I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
ClinicalTrials.gov · NCT04488081 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 55%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
8w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
8w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
4mo agoTrial registeredSource (opens the source filing in a new tab)
NIH R13 · $0.0M · RISE UP for Breast Cancer 2026
5mo agoNew grantSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R13 · $13k · non-dilutive

PHASE2 registered

PHASE2 registered